The University of Oxford undertook the task of coming up with their own COVID-19 vaccine through a tie-up with pharmaceutical company AstraZeneca. The net result was the creation of a vaccine named AZD1222, which is a top contender in the current COVID vaccine race
• January 2 2021
AstraZeneca becomes the first Covid 19 vaccine to be approved for everyday use by India.
• January 12 2021
AstraZeneca and Oxford University have filed a formal authorisation for their Coronavirus vaccine.
The decision is to be expected on 29 January by EMA.
Britain, India and Argentina have already approved the emergency use of vaccine.
Latest Update (8th December): AstraZeneca-Oxford University Rush to Seek Emergency Approval in India
● The SII has filed for the emergency use authorisation (EUA) of Covishield vaccine in the midst of its Phase-3 trials, which are currently being conducted not just across India, but also in the UK and Brazil.
● In India, the trials have been co-sponsored by the country’s apex medical body, the Indian Council of Medical Research (ICMR).
● For the emergency approvals, the SII has shared the interim data of four clinical trials—one each from India and Brazil, and two trials from the UK—with the DCGI.
● One of the major advantages of this vaccine candidate, which is being made in collaboration with AstraZeneca and Oxford University, is that it can be easily stored at temperatures between 2 to 8°C.
AstraZeneca: The Oxford University vaccine against COVID-19 being produced by AstraZeneca is likely to get regulatory approval from the UK's independent regulator by the end of this year
● The Medicines and Healthcare Regulatory Agency (MHRA), which had been formally tasked by the UK government last month with the process of clearance after the jab emerged safe and effective against the novel coronavirus in human trials, is expected to authorise the vaccine by December 28 or 29 after the final data is provided on Monday.
● Authorisation by the MHRA will also give confidence to countries across the world. India has already manufactured more than 50 million of the AstraZeneca vaccines, the newspaper notes.
● Health officials in the UK hope that the authorisation of the Oxford jab will prove a game-changer, allowing vaccines to be transported and administered far more easily compared to the Pfizer/BioNTech vaccine which must be stored at very cold temperatures.
● The Oxford/AstraZeneca vaccine, AZD1222, has taken longer for regulators to assess because of differences in the efficacy rates found in different groups, ranging from 62 to 90 per cent. However, a study released this week suggests that leaving an adequate gap between doses is the most crucial way to boost efficacy, the newspaper reports.
● Although the first batch of 4 million doses will be delivered from the Netherlands and Germany, the bulk of manufacturing is set to take place in the UK.
● Pharmaceutical giant AstraZeneca has said a further 15 million doses of active ingredients are ready and can be filled into vials in a matter of days.
Update: 14th December, 2020
AstraZeneca: Oxford-AstraZeneca's COVID-19 vaccine can be available in the country as early as the first half of next year, AstraZeneca Country President Gagandeep Singh has said.
● Speaking at the 93rd annual convention of industry chamber FICCI, he said the vaccine has to be made available broadly, equitably, and in a timely manner in the current pandemic.
● Pune-based Serum Institute of India is conducting clinical trials of Oxford University-AstraZeneca's COVID-19 vaccine candidate Covishield in India.
Update (26th November): The AstraZeneca vaccine has been found only 70% effective overall.
● AstraZeneca and Oxford University have acknowledged a manufacturing error which has raised questions about preliminary results of their experimental Covid-19 vaccine.
● The vaccine was given to two groups in two separate dosage forms - a low-dose group and a high-dose group.
● In the low-dose group, AstraZeneca said, the vaccine appeared to be 90 per cent effective. In the group that got two full doses, the vaccine appeared to be 62 per cent effective. Combined, the drugmakers said the vaccine appeared to be 70 per cent effective.
Also read - Moderna COVID 19 Vaccine status in india.
Country of origin: Britain ( Cambridge, England)
Phase 1 trial results:
● Strong immune response in older adults
● The robust antibody and T-cell responses seen in older people
● Volunteers got two doses of the vaccine or a placebo, and no serious side effects related to the AZD1222 vaccine
● Late-stage, or Phase III, trials are ongoing to confirm the findings,
● 95 per cent efficacy in the late-stage trial.
● Transverse myelitis produces a set of symptoms involving inflammation along the spinal cord that can cause pain
● Muscle weakness and paralysis.
According to a press release from the company on 23rd November, 2020, the vaccine AZD1222 reached the primary endpoint of efficacy in the prevention of COVID-19 when tested in the UK and Brazil, with no reported hospitalizations yet.
Must Read - Bharat Biotech coronavirus Vaccine Update in india